List of Vabomere drug patents
Vabomere is owned by Rempex.
Vabomere contains Meropenem; Vaborbactam.
Vabomere has a total of 7 drug patents out of which 0 drug patents have expired.
Vabomere was authorised for market use on 29 August, 2017.
Vabomere is available in powder;intravenous dosage forms.
Vabomere can be used as treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified, treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms, treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified, treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex.
Drug patent challenges can be filed against Vabomere from 2026-08-29.
The generics of Vabomere are possible to be released after 06 April, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 2026-08-29
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelon...
Dosage: POWDER;INTRAVENOUS
VABOMERE family patents
24
United States
5
Japan
4
Hungary
4
Korea, Republic of
4
European Union
3
Lithuania
2
Denmark
2
Mexico
2
Australia
2
Norway
2
Singapore
2
Brazil
2
Portugal
2
Spain
2
Poland
2
Chile
2
China
2
Canada
1
Israel
1
Turkey
1
Jordan
1
Slovenia
1
Russia
1
Philippines
1
Colombia
1
Croatia
1
Malaysia
1
Taiwan, Province of China
1
RS
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic